DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

1064 Nathani N, Little MA, Kunst H, et al. Churg-Strauss syndrome
and leukotriene antagonist use: A respiratory perspective.
Thorax, 2008, 63:883–888.
Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol
Multicenter Asthma Research Trial: A comparison of usual
pharmacotherapy for asthma or usual pharmacotherapy plus
salmeterol. Chest, 2006, 129:15–26.
Newton PJ, Davidson PM, Macdonald P, et al. Nebulized
furosemide for the management of dyspnea: Does the evidence
support its use? J Pain Symptom Manage, 2008, 36:424–441.
Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic
glucocorticoids on exacerbations of chronic obstructive
pulmonary disease. N Engl J Med, 1999, 340:1941–1947.
Nightingale JA, Rogers DF, Barnes PJ. Comparison of the effects
of salmeterol and formoterol in patients with severe asthma.
Chest, 2002, 121:1401–1406.
O’Byrne PM, Pedersen S, Busse WW, et al. Effects of early intervention
with inhaled budesonide on lung function in newly
diagnosed asthma. Chest, 2006, 129:1478–1485.
O’Sullivan S, Akveld M, Burke CM, Poulter LW. Effect of the
addition of montelukast to inhaled fluticasone propionate on
airway inflammation. Am J Respir Crit Care Med, 2003,
167:745–750.
Ohta K, Yamashita N. Apoptosis of eosinophils and lymphocytes
in allergic inflammation. J Allergy Clin Immunol, 1999,
104:14–21.
Oliver B, Tomita K, Keller A, et al. Low-dose theophylline does
not exert its anti-inflammatory effects in mild asthma through
upregulation of interleukin-10 in alveolar macrophages.
Allergy, 2001, 56:1087–1090.
Parameswaran K, Belda J, Rowe BH. Addition of intravenous
aminophylline to beta2-agonists in adults with acute asthma.
Cochrane Database Syst Rev, 2000, CD002742.
Pavord ID, Chung KF. Management of chronic cough. Lancet,
2008, 371:1375–1384.
Pedersen S. Do inhaled corticosteroids inhibit growth in children?
Am J Respir Crit Care Med, 2001, 164:521–535.
Pelaia G, Gallelli L, Vatrella A, et al. Potential role of potassium
channel openers in the treatment of asthma and chronic
obstructive pulmonary disease. Life Sci, 2002, 70:977–990.
Peters-Golden M, Henderson WR Jr. Leukotrienes. N Engl J
Med, 2007, 357:1841–1854.
Pettipher R, Hansel TT, Armer R. Antagonism of the
prostaglandin D2 receptors DP1 and CRTH2 as an approach to
treat allergic diseases. Nat Rev Drug Discov, 2007, 6:313–325.
Poole PJ, Black PN. Oral mucolytic drugs for exacerbations of
chronic obstructive pulmonary disease: Systematic review.
BMJ, 2001, 322:1271–1274.
Rabe KF, Atienza T, Magyar P, et al. Reduction in exacerbations
with budesonide in combination with formoterol for reliever
therapy: A randomised, controlled double-blind study. Lancet,
2006, 368:707–708.
Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis,
management, and prevention of COPD—2006 update.
Am J Respir Crit Care Med, 2007, 176:532–555.
Ram FS, Jones PW, Castro AA, et al. Oral theophylline for
chronic obstructive pulmonary disease. Cochrane Database
Syst Rev, 2002, CD003902.
Ray NC, Alcaraz L. Muscarinic antagonist-beta-adrenergic agonist
dual pharmacology molecules as bronchodilators: A patent
review. Expert Opin Ther Pat, 2009, 19:1–12.
SECTION IV
INFLAMMATION, IMMUNOMODULATION, AND HEMATOPOIESIS
Rennard SI, Fogarty C, Kelsen S, et al. The safety and efficacy
of infliximab in moderate-to-severe chronic obstructive
pulmonary disease. Am J Respir Crit Care Med, 2007,
175:926–934.
Rivington RN, Boulet LP, Cote J, et al. Efficacy of slow-release
theophylline, inhaled salbutamol and their combination in
asthmatic patients on high-dose inhaled steroids. Am J Respir
Crit Care Med, 1995, 151:325–332.
Robinson DS, Campbell DA, Barnes, PJ. Addition of an antileukotriene
to therapy in chronic severe asthma in a clinic setting:
A double-blind, randomised, placebo-controlled study.
Lancet, 2001, 357:2007–2011.
Rodrigo GJ, Nannini LJ, Rodriguez-Roisin R. Safety of longacting
beta-agonists in stable COPD: A systematic review.
Chest, 2008, 133:1079–1087.
Rogers DF. Pharmacological regulation of the neuronal control of
airway mucus secretion. Curr Opin Pharmacol, 2002, 2:249–255.
Rogers DF, Barnes PJ. Treatment of airway mucus hypersecretion.
Ann Med, 2006, 38:116–125.
Rolland JM, Gardner LM, O’Hehir RE. Allergen-related
approaches to immunotherapy. Pharmacol Ther, 2009,
121:273–284.
Schacke H, Berger M, Rehwinkel H, Asadullah K. Selective glucocorticoid
receptor agonists (SEGRAs): Novel ligands with
an improved therapeutic index. Mol Cell Endocrinol, 2007,
275:109–117.
Sears MR, Taylor DR, Print CG, et al. Regular inhaled betaagonist
treatment in bronchial asthma. Lancet, 1990, 336:
1391–1396.
Seddon P, Bara A, Ducharme FM, Lasserson TJ. Oral xanthines
as maintenance treatment for asthma in children. Cochrane
Database Syst Rev, 2006, CD002885.
Shah L, Wilson AJ, Gibson PG, Coughlan J. Long acting betaagonists
versus theophylline for maintenance treatment of
asthma. Cochrane Database Syst Rev, 2003, CD001281.
Sin DD, Tashkin D, Zhang X, et al. Budesonide and the risk of
pneumonia: A meta-analysis of individual patient data. Lancet,
2009, 374:712–719.
Singh D, Richards D, Knowles RG, et al. Selective inducible
nitric oxide synthase inhibition has no effect on allergen challenge
in asthma. Am J Respir Crit Care Med, 2007,
176:988–993.
Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids
and the risk of pneumonia in chronic obstructive pulmonary
disease: A meta-analysis. Arch Intern Med, 2009,
169:219–229.
Skorodin MS, Tenholder MF, Yetter B, et al. Magnesium sulfate
in exacerbations of chronic obstructive pulmonary disease.
Arch Intern Med, 1995, 155:496–500.
Spitzer WO, Suissa S, Ernst P, et al. The use of -agonists and
the rate of death and near-death from asthma. N Engl J Med,
1992, 326:503–506.
Sturton G, Persson C, Barnes PJ. Small airways: An important
but neglected target in the treatment of obstructive airway diseases.
Trends Pharmacol Sci, 2008, 29:340–345.
Suissa S, Ernst P, Benayoun S, et al. Low-dose inhaled corticosteroids
and the prevention of death from asthma. N Engl J
Med, 2000, 343:332–336.
Suissa S, Ernst P, Vandemheen KL, Aaron SD. Methodological
issues in therapeutic trials of COPD. Eur Respir J, 2008,
31:927–933.